石四藥集團有限公司
SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT
UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that the Group has obtained the approvals for drug production and registration for the following four products from National Medical Products Administration of China, all being under type 4 chemical drug and regarded as passing the consistency evaluation.

1. Hemofiltration Replacement Fluid of Sodium Citrate (5000ml): This product is mainly used as a replacement fluid in continuous renal replacement therapy (CRRT) with local citrate anticoagulation, and is particularly suitable for patients such as those with an increased risk of bleeding who are not advised for systemic anticoagulation with heparin.

   Compared to clinical mainstream split citrate formula (bicarbonate replacement fluid combined with a separate sodium citrate anticoagulant), this product has significant clinical advantages and a promising market prospect. The Group is actively developing large-volume injections such as hemofiltration replacement solutions and peritoneal dialysis solutions, further improving its product portfolio.

2. Benidipine Hydrochloride Tablets (4mg): This product is mainly used for the treatment of primary hypertension and angina pectoris.

   The Group has established a comprehensive hypertension product portfolio, covering 2nd and 3rd generation calcium channel blockers, ACE inhibitors, α-receptor blockers, and multiple single-tablet compound preparations, along with intravenous emergency antihypertensive drugs used in intensive care unit (ICU). Among which, the Group's Benidipine Hydrochloride Tablets in 8mg specification has been approved for market and selected in the tender result of the eleventh batch of the National Centralised Medicines Procurement. With the approval of its 4mg specification, the initial low-dose treatment needs for hypertension can be fully met, forming a complete dose gradient of "initial titration 4mg + maintenance therapy 8mg".

3. Polyvinyl Alcohol Eye Drops 1.4% (0.4ml: 5.6mg): This product is mainly used as a lubricant for prevention or treatment of irritation symptoms such as dry eyes, foreign matter sensation and eye fatigue, or for improvement of eye dryness symptoms.

   Polyvinyl Alcohol Eye Drop is in single-dose packaging, preservative-free, and is an OTC product for office workers experiencing eye strain, people spending long time at screens or with sensitive ocular surfaces for their immediate relief of dry eyes. The Group has a strategic layout in ophthalmic drug segment with single-dose and preservative-free formulations, and has built a product portfolio including anti-infectives, anti-allergens, intraocular pressure lowering, artificial tears and ocular anti-inflammatory, forming a dual-channel layout of in-hospital prescription drugs and retail OTC.

4. Fat Emulsion, Amino Acids (17) and Glucose (19%) Injection (1540ml and 1026ml): This product is mainly used for adult patients who are unable, with impaired function or not advised for receiving nutrition orally or enterally.

   This product is a complex three-chamber bag preparation for parenteral nutrition with high technological barriers. It is mainly used for intravenous nutritional support in adult patients after surgery, those with tumors or in ICU. The newly approved 1540ml and 1026ml specifications can meet the individualised clinical needs of patients with different weights and energy requirements.

   The Group is systematically developing a parenteral nutrition product platform covering premixed three-chamber bag all-in-one preparations, nutrients, vitamins, trace elements and electrolyte supplements. This approval further enhances the Group's high-end intravenous nutrition product portfolio, creating synergy with its basic infusion, amino acid and fat emulsion series, and will bring a positive effect on its expansion into the perioperative and critical care nutrition markets.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 23 July 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.